A recent study conducted by researchers at Shoolini University, India, finds that disturbed circadian rhythm can disrupt normal physiological functions and cause hyperactivity, anxiety, and memory deficits, increasing the risk of developing neurological disorders such as Alzheimer’s disease
Circadian rhythm disruption adversely affects the physiology and behavior of rats, with implications in Alzheimer’s disease pathology
Disturbed circadian rhythm, which can even be caused by chronic light exposure, affects normal physiological functions, resulting in anxiety, hyperactivity, and memory deficits. These disruptions, often caused by stressful modern lifestyles, cause severe neurological changes, including Alzheimer’s disease. Now, researchers from Shoolini University, India, investigate the cause-and-effect relationship between aberrant circadian rhythms and Alzheimer’s disease pathology in rats exposed to light for prolonged periods, and report that the anti-depressant fluoxetine may alleviate these neurological symptoms.
Our body is tuned to function in a synchronous manner with a “circadian” or day-and-night rhythm. Alterations to daily lifestyles due to the current stressful routines people follow disrupt the body’s day-night cycle for longer periods. Recent studies in rats have shown that even chronic light exposure can disrupt the circadian rhythm and cause memory deficits seen in neurological disorders such as Alzheimer’s disease (AD). Interestingly, circadian rhythm disruption has also been frequently reported in patients suffering from AD. However, the cause-and-effect relationship between AD and circadian rhythm disruption remains unclear.
To understand the correlation between circadian rhythm disturbances and AD progression, a team of researchers from Shoolini University, India, tested the effect of circadian rhythm disruption caused by chronic light exposure on the physiology and functional abilities of Wistar rats. Explaining the rationale behind their study published in ACS Chemical Neuroscience (American Chemical Society), Professor Rohit Goyal, who led the study, said, “Cells of various organs in the body are synchronized to the day-night cycle, and release different biochemical substances including hormones in a time-specific manner. Untimely expression of these hormones can trigger anxiety, cognitive impairment, and memory loss, all symptoms of brain disorders such as AD.”
In a previous study, the team had reported that upon chronic light exposure for two months, rats exhibit cognitive deficits along with sub-clinical accumulation of amyloid β (Aβ), the pathogenic protein known to form aggregates in AD. Building on these findings, they speculated that longer light exposure may result in circadian rhythm disruptions that cause an AD-like phenotype. To test this hypothesis, they exposed adult rats to constant light conditions for four months and compared them with rats subjected to a normal light-dark cycle taken as the control group.
They found that chronic light exposure disrupted the expression of genes like Per2 that follow circadian rhythms. Markers of oxidative stress such as peroxiredoxins were also dysregulated in the suprachiasmatic nuclei (SCN) region of the brain in these rats, which is the primary controller of circadian rhythms in the body. Neurotransmitters, including glutamate and γ-aminobutyric acid, were dysregulated in the SCN of rats with circadian rhythm disruption due to chronic light exposure. Additionally, these animals showed disrupted metabolic profiles, suggestive that their digestive systems may also have been adversely affected by the disrupted circadian rhythms.
The level of soluble Aβ in the brain was also significantly higher in these rats compared to the controls, and they experienced down-regulation of anti-aging gene Sirt1 and up-regulation of the neuronal damage markers. The researchers also found that circadian rhythm disruption due to chronic light exposure caused memory and cognitive deficits in the rats. Collectively, these findings were suggestive of an AD-like phenotype.
Based on the above results, their next hypothesis was that fluoxetine, a drug used for treating anxiety and hyperactivity, could alleviate physiological and functional abnormalities associated with circadian rhythm disruption. Sure enough, fluoxetine treatment prevented oxidative damage, Aβ accumulation, and rescued memory and cognitive deficits in the treated rats.
Overall, the study suggests that long-term circadian rhythm disruption induces AD-like pathology in rats, which can be prevented by treatment with fluoxetine. Notably, elevation in Aβ, a hallmark of AD, and disturbed circadian rhythm can each trigger the other, resulting in a cascade of irreversible neurological symptoms. This sets the stage for serious life-long conditions like AD.
The clinical implications of their findings are also evident. Prof. Goyal remarks, “Lifestyle changes that support exposure to natural light followed by ample rest at night may thus be key to limiting the risk of neurological disorders. Therapeutic strategies to optimize circadian timing in prospective patients hold great promise to restrain the prevalence of AD”. Better lifestyle practices, following the traditional Indian discipline of Yoga, or maintaining a natural day-night cycle for work schedules and even dietary practices may make our bodies healthier and function better.
This study certainly “sheds light” on the cause-and-effect relationship between circadian rhythms and AD progression, paving the way for future investigations on this important topic.
|Authors||Ashish Sharma , ^Ashu Mohammad, # Adesh K. Saini, and Rohit Goyal|
|Title of original paper||Neuroprotective Effects of Fluoxetine on Molecular Markers of|
Circadian Rhythm, Cognitive Deficits, Oxidative Damage, and
Biomarkers of Alzheimer’s Disease-Like Pathology Induced under
Chronic Constant Light Regime in Wistar Rats
|Journal||ACS Chemical Neuroscience|
|Affiliations||*Neuropharmacology Laboratory, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, India|
^ School of Biotechnology and Applied Sciences, Shoolini University, Himachal Pradesh 173212, India
#Department of Biotechnology and Central Research Cell, Haryana, India
About Professor Rohit Goyal
Professor Rohit Goyal is currently a faculty member at the Neuropharmacology Laboratory, School of Pharmaceutical Sciences, Shoolini University, India, and has completed his Ph.D. from Punjab Technical University. Prof. Rohit Goyal holds over 14 years of teaching and research experience in the field of Pharmacy and Pharmacology. His area of research includes molecular targets of Alzheimer’s disease, life-style disorders, circadian rhythm dysfunction, pre-clinical pharmacology, osteoporosis, asthma, and natural products.